EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Lisa Licitra, Robert L. Ferris, С. И. Кутукова et al.|Journal of Clinical Oncology|2019

Cited by 39